"In this episode Tim chats with Matt Callahan, executive director of Botanix Pharmaceuticals (ASX:BOT).
Botanix is a clinical stage synthetic cannabinoid company focused on the development of pharmaceutical products.
The company has two separate cannabinoid development platforms, dermatology and antimicrobial products, both of which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol.
Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.
"
Ann: Appendix 4C - Quarterly, page-21
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $3.051M | 8.277M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 465836 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 301865 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |